Ischemic Cardiomyopathy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Ischemic Cardiomyopathy – Drugs In Development, 2024 report and make more profitable business decisions.
Ischemic cardiomyopathy is a type of cardiomyopathy caused by a narrowing of the coronary arteries that supply blood to the heart. Patients with ischemic cardiomyopathy often have a history of acute myocardial infarction (MI), but it may occur in patients with coronary artery disease but no past history of acute MI. This cardiomyopathy is one of the leading causes of sudden cardiac death. The adjective ischemic means it is characteristic of, or accompanied by, local anemia due to mechanical obstruction of the blood supply.
The Ischemic Cardiomyopathy drugs in development market research report provide comprehensive information on the therapeutics under development for Ischemic Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ischemic Cardiomyopathy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Ischemic Cardiomyopathy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 10 molecules, with 8 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Ischemic Cardiomyopathy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Ischemic Cardiomyopathy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Ischemic Cardiomyopathy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Celixir LtdCoBioRes NV
Cuorips Inc
Hemostemix Inc
iHeart Japan Corp
Osaka University Hospital
Rohto Pharmaceutical Co Ltd
Shionogi & Co Ltd
University of California San Francisco
Viscofan BioEngineering
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Ischemic Cardiomyopathy reports